Display Settings:

Format

Send to:

Choose Destination
    Parasite Immunol. 2011 Dec 28. doi: 10.1111/j.1365-3024.2011.01351.x. [Epub ahead of print]

    Leishmania (Viannia) braziliensis antigenic fractions: the immune response characterization of patients at the initial phase of disease.

    Source

    Departamento de Imunologia, Centro de Pesquisas Aggeu Magalhães (CPqAM/FIOCRUZ), Recife, PE, Brasil Departamento de Dermatologia, Universidade de Pernambuco, Recife, PE, Brasil.

    Abstract

    American cutaneous leishmaniasis (ACL) has different clinical manifestations and those are dependent on the immunological status of the host. Since CD4(+) and CD8(+) T cells and its mediators play a fundamental role in the host response to Leishmania and that there is also a search for antigenic molecules to be used as future vaccines and tools for prognostic tests, this study characterized ACL patients immune response after stimulation with soluble and insoluble fractions of L. (V.) braziliensis. We demonstrated a prevailing production of the Th2 cytokines, IL-4 and IL-10, and a specific production of IFN-γ and TNF-α in patients before treatment. There was also a predominance of CD4(+) T cells and a small percentage CD8(+) T cells. The insoluble antigenic fraction primarily stimulated CD4(+) T cells while the soluble antigenic fraction showed a mixed profile, with CD4(+) T cells being the main responsible for Th2 cytokines and CD8(+) T cells for Th1 cytokines. Therefore, our results showed that a down modulation of the Th1 type of response occurs in the initial phase of L. braziliensis disease being the antigenic fractions capable of stimulating a specific immune response. © 2011 Blackwell Publishing Ltd.

    © 2011 Blackwell Publishing Ltd.

    PMID:
    22211531
    [PubMed - as supplied by publisher]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk